NJ Bio and Ajinomoto Bio-Pharma Join Forces to Advance Antibody-Drug Conjugate Development NJ Bio, Inc. and Ajinomoto Bio-Pharma Services have teamed up to enhance the capabilities of antibody-drug conjugate development, promising improved therapeutic options for patients.

NJ Bio and Ajinomoto Bio-Pharma Join Forces to Advance Antibody-Drug Conjugate Development #USA #Princeton #Ajinomoto #AJICAP #NJ_Bio

Innovative Research Enhances Pharmacokinetics of Nucleic Acid Aptamers in Collaboration with Ajinomoto and RIBOMIC Ajinomoto Co., Inc. and RIBOMIC Inc. have made significant strides in extending the pharmacokinetics of nucleic acid aptamers using cutting-edge technology, promising advancements in drug efficacy.

Innovative Research Enhances Pharmacokinetics of Nucleic Acid Aptamers in Collaboration with Ajinomoto and RIBOMIC #Japan #Tokyo #Ajinomoto #RIBOMIC #AJICAP